Todd Tushla | VP, IR |
Kevin Gorman | CEO & Director |
Matthew Abernethy | CFO |
Eric Benevich | Chief Commercial Officer |
Eiry Roberts | Chief Medical Officer |
Kyle Gano | Chief Business Development and Strategy Officer |
Paul Matteis | Stifel, Nicolaus & Company |
Brian Skorney | Robert W. Baird & Co. |
Carter Gould | Barclays Bank |
Neena Bitritto-Garg | Citigroup |
Tazeen Ahmad | Bank of America Merrill Lynch |
Joshua Schimmer | Evercore ISI |
Anupam Rama | JPMorgan Chase & Co. |
Charles Duncan | Cantor Fitzgerald & Co. |
Philip Nadeau | Cowen and Company |
Jeff Hung | Morgan Stanley |
Chris Shibutani | Goldman Sachs Group |
Jay Olson | Oppenheimer |
Laura Chico | Wedbush Securities |
Marc Goodman | SVB Leerink |
Vamil Divan | Mizuho Securities |
Myles Minter | William Blair & Company |
Yatin Suneja | Guggenheim Securities |
Good day, everyone, and welcome to today's Neurocrine Biosciences Reports First Quarter Results. [Operator Instructions]. It is now my pleasure to turn today's program over to Todd Tushla, VP of Investor Relations.
Thank you, operator. Good morning, everyone, and thanks for joining our first quarter 2022 earnings call.